Comparative Pharmacology
Head-to-head clinical analysis: FUNGIZONE versus NOXAFIL POWDERMIX KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNGIZONE versus NOXAFIL POWDERMIX KIT.
FUNGIZONE vs NOXAFIL POWDERMIX KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability, leading to leakage of intracellular contents and cell death.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
IV: 0.25-1 mg/kg/day as a single infusion; for aspergillosis, up to 1.5 mg/kg/day; maximum daily dose 1.5 mg/kg.
300 mg (one 300-mg vial) intravenously twice on day 1, then 300 mg intravenously once daily starting on day 2. Alternatively, oral suspension: 200 mg (10 mL) three times daily. For prophylaxis, IV: 300 mg twice on day 1, then 300 mg once daily; oral: 200 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 15 days (range 10-20 days) after a single dose; with prolonged therapy, a prolonged terminal half-life of up to 15 days reflects slow redistribution from tissue depots.
The terminal elimination half-life is approximately 27 hours (range 20-66 hours) in healthy subjects, allowing for once-daily dosing after steady state.
Primarily fecal (40-50%) via biliary elimination without metabolism; renal excretion of unchanged drug is minimal (<5% in 24 hours).
Posaconazole is primarily excreted in the feces (77%) as unchanged drug, with renal excretion accounting for 14% of the dose (primarily as glucuronide conjugates). Less than 0.2% is excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal